Eikon Therapeutics, Inc. Stock: price and insider trades · United States

Every trade that managers of Eikon Therapeutics, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. Over the twelve months to 22 October 2026, 35 filings were filed, from 6 insiders.

Every open-market trade in the period is a purchase: 7 purchases worth €37.9M, from 4 insiders, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Those buying include 2 major shareholders and 2 senior executives. One trade stands out by size: a purchase of €22.0M from Column Group IV GP, LP, disclosed on 9 February 2026.

In all, 2 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 46 days ago, on 8 September 2026. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.

Across the 5,462 companies tracked on its exchange, the median is 28 filings; at 35 filings, this issuer sits above that mark. Over the whole record (from 2026), the tally stands at 7 purchases and no sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.